Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Turoctocog Alfa in Pediatric Hemophilia A
NCT01138501Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2010
- Primary completion
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Incidence Rate of FVIII Inhibitors at 138 days. Started Jun 2010; status: completed.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01138501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138501.